Faculty profile

Arnim Pause

ResearcherBiochemistryMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Arnim Pause

Researcher

Biochemistry

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2026.
Supervised 3 trainees who won CIHR awards, most recently in 2017.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

5,140

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Drug Resistance Ampk Flcn Breast Cancer Metastasis Autophagy Cancer Progression Hypoxia

Latest papers

Ninth BHD International Symposium: Advancing research through global collaboration.
Cell stress & chaperones · 2026
Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysis.
Oncogene · 2025
Measuring EGFR plasma membrane density, stability, internalization, and recycling in alive adherent cells by cell surface ELISA.
STAR protocols · 2022 · senior author

All 44 publications

Latest funding

Targeting the AMPK-FLCN-TFE3 Oxygen-Sensing Pathway to Overcome Hypoxic Tumor Adaptation
CIHR · 2026 · Nominated PI
$937,126
Characterization of human TFE3 isoforms as drivers in breast cancer
CIHR · 2022 · Nominated PI
$100,000
Interplay of AMPK and mTOR pathways at the lysosome: starvation, nutrient availability and metabolic disease.
CIHR · 2019 · Nominated PI
$956,250

All 12 grants and awards

44 publications.

Ninth BHD International Symposium: Advancing research through global collaboration.

Rajan N, Baba M, Ballabio A, Henske EP, Jacques K, Marciniak SJ, Pause A, Shi W, Soleimani M, Tee AR, Zoncu R, Mollapour M, Linehan WM

Cell stress & chaperones2026

DOI: 10.1016/j.cstres.2026.100184 PMID: 42155667

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysis.

Jones RA, Dunlop EA, Champion JD, Doubleday PF, Claessens T, Jalali Z, Seifan S, Perry IA, Giles P, Harrison O, Coull BJ, Houweling AC, Pause A, Ballif BA, Tee AR

Oncogene2025

DOI: 10.1038/s41388-025-03325-z PMID: 40133475

Measuring EGFR plasma membrane density, stability, internalization, and recycling in alive adherent cells by cell surface ELISA.

Kazan JM, Pollato-Blanco A, Lukacs GL, Pause A

STAR protocols2022Senior author

DOI: 10.1016/j.xpro.2022.101475 PMID: 35755125

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.

Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM

Oncogene2022

DOI: 10.1038/s41388-022-02206-z PMID: 35110681

Seventh BHD international symposium: recent scientific and clinical advancement.

Woodford MR, Andreou A, Baba M, van de Beek I, Di Malta C, Glykofridis I, Grimes H, Henske EP, Iliopoulos O, Kurihara M, Lazor R, Linehan WM, Matsumoto K, Marciniak SJ, Namba Y, Pause A, Rajan N, Ray A, Schmidt LS, Shi W, Steinlein OK, Thierauf J, Zoncu R, Webb A, Mollapour M

Oncotarget2022

DOI: 10.18632/oncotarget.28176 PMID: 35070081

AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3.

Paquette M, El-Houjeiri L, C Zirden L, Puustinen P, Blanchette P, Jeong H, Dejgaard K, Siegel PM, Pause A

Autophagy2021Senior author

DOI: 10.1080/15548627.2021.1898748 PMID: 33734022

Endofin is required for HD-PTP and ESCRT-0 interdependent endosomal sorting of ubiquitinated transmembrane cargoes.

Kazan JM, Desrochers G, Martin CE, Jeong H, Kharitidi D, Apaja PM, Roldan A, St Denis N, Gingras AC, Lukacs GL, Pause A

iScience2021Senior author

DOI: 10.1016/j.isci.2021.103274 PMID: 34761192

Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways.

Paquette M, Yan M, Ramírez-Reyes JMJ, El-Houjeiri L, Biondini M, Dufour CR, Jeong H, Pacis A, Giguère V, Estall JL, Siegel PM, Audet-Walsh É, Pause A

Scientific reports2021Senior author

DOI: 10.1038/s41598-021-99958-7 PMID: 34711912

Folliculin: A Regulator of Transcription Through AMPK and mTOR Signaling Pathways.

Ramirez Reyes JMJ, Cuesta R, Pause A

Frontiers in cell and developmental biology2021Senior author

DOI: 10.3389/fcell.2021.667311 PMID: 33981707

The dead phosphatases society: a review of the emerging roles of pseudophosphatases.

Reiterer V, Pawłowski K, Desrochers G, Pause A, Sharpe HJ, Farhan H

The FEBS journal2020

DOI: 10.1111/febs.15431 PMID: 32484316

Targeting the AMPK-FLCN-TFE3 Oxygen-Sensing Pathway to Overcome Hypoxic Tumor Adaptation

Nominated PICIHR2026Project Grant

Principal investigators: Pause, Arnim P

Keywords: Ampk; Autophagy; Breast Cancer; Cancer Progression; Drug Resistance; Flcn; Hypoxia; Mitochondria Biogenesis; Mtorc

$937,126

Characterization of human TFE3 isoforms as drivers in breast cancer

Nominated PICIHR2022Project Grant - PA: Breast Cancer Research

Principal investigators: Pause, Arnim P

Keywords: Breast Cancer; Metastasis; Tfe3; Tnbc; Transcription; Tumor Progression

$100,000

Interplay of AMPK and mTOR pathways at the lysosome: starvation, nutrient availability and metabolic disease.

Nominated PICIHR2019Project Grant

Principal investigators: Pause, Arnim P

Keywords: Ampk; Flcn; Metabolic Syndrome; Mtor; Obesity; Phosphorylation; Tfeb

$956,250

New treatments of neurodegenerative diseases involving the cellular recycling machinery

SupervisorCIHR2017Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Paquette, Mathieu

Keywords: Autophagy/Lysosome; Immunofluorescence; Immunohistochimie; Maladie D'Alzheimer; Maladie De Parkinson; Maladies Neurodégénératives; Modèles De Souris; Modèles De Vers (C.Elegans); Phosphorylation; Signalisation Moléculaire

$105,000

Haploinsufficient loss of ESCRT components as new drivers of cancer

Nominated PICIHR2016Project Grant

Principal investigators: Pause, Arnim P

Keywords: Cell Surface Receptors; Cre-Lox Mouse Models; Drug Resistance; Endosomal Sorting Complexes Required For Transport (Escrt); Haploinsufficiency; Lung Cancer; Lymphoma; Metastasis; Targeted Therapies; Tumor Suppressor Genes

$956,250

Mechanisms of Met activation in cancer and therapeutic intervention

Co-investigatorCIHR2014Foundation Grant

Principal investigators: Park, Morag

Keywords: Cell Signalling Networks; Gastric Cancer; Gene Expression; Growth Factor; Intracellular Trafficking; Oncogenic Activation; Preclinical Models; Receptor Tyrosine Kinase; Resistance; Triple Negative Breast Cancer

$3,507,282

Characterization of the role of FLCN, a novel AMPK-interacting protein, in adipose tissue metabolism

SupervisorCIHR2011Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Yan, Ming

Keywords: Biochemistry; Clone/Subclone; Genetics; Immunology; Metabolism And Desease; Molecular Biology; Obesity; Protein Manipulation And Expression; Rnai/Shrna; Tumor Supressor

$105,000

HCV genetic variability and resistance to antiviral drugs

Co-investigatorCIHR2011Operating Grant

Principal investigators: Götte, Matthias

Keywords: Antiviral Drugs; Biochemical Mechanisms; Drug Resistance; Enzyme Kinetics; Fidelity; Genotype; Hcv Replicons; Hepatitis C Virus (Hcv); Jfh-1; Rna Polymerase

$410,430

Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities.

Principal investigatorCIHR2010Team Grant: Terry Fox New Frontiers Program in Cancer

Principal investigators: Tremblay, Michel L; Jones, Russell G; Pause, Arnim P; Sonenberg, Nahum; St-Pierre, Julie

Keywords: Amp Kinase; Anima Models Phenotyping; Bioenergetics; Cancer Prevention And Therapies; Cell Signaling; Oncometabolism; Protein Synthesis; Transcription Regulation Of Metabolic Genes; Tyrosine Phosphorylation; Warburg Effect

Characterizing the function of the von Hippel Lindau tumor suppressor in tumorigenesis and angiogenesis

SupervisorCIHR2009Master's Award: Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Panneton, Vanessa

Keywords: Angiogenesis; Binding Partners; Cancer; Collagen; Extracellular Matrix; Hypoxia; Kidney; Mouse Model; Tumor Suppressor; Von Hippel Lindau (Vhl)

$17,500

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Arnim Pause

Research

Latest papers

Latest funding

Ninth BHD International Symposium: Advancing research through global collaboration.

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dub&#xe9; syndrome cell models through transcriptomic and proteomic analysis.

Measuring EGFR plasma membrane density, stability, internalization, and recycling in alive adherent cells by cell surface ELISA.

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.

Seventh BHD international symposium: recent scientific and clinical advancement.

AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3.

Endofin is required for HD-PTP and ESCRT-0 interdependent endosomal sorting of ubiquitinated transmembrane cargoes.

Loss of hepatic&#xa0;Flcn protects against fibrosis and inflammation by activating autophagy pathways.

Folliculin: A Regulator of Transcription Through AMPK and mTOR Signaling Pathways.

The dead phosphatases society: a review of the emerging roles of pseudophosphatases.

Frequent collaborators

Nahum Sonenberg

Julie St-Pierre

Simon-Pierre Gravel

Ivan Topisirovic

Ivan Topisirovic

Jerry Pelletier

Anne-Claude Gingras

Julie St-Pierre

Xi-Long Zheng

Morag Park

Urban Emmenegger

Michael Pollak

Julianna Blagih

Tommy Alain

Ruth Slack

Craig McCormick

Thomas Duchaine

Honglin Luo

Russell Jones

Sidong Huang

Maxime Bouchard

Eldad Zacksenhaus

Isabella Caniggia

Xiaoyan Jiang

Michel Roberge

Morag Park

Steve Jean

Jacek Majewski

Dusica Maysinger

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysis.

Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways.